Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Novalix S.A.S.. (11/18/13). "Press Release: The Novalix / Kyowa Hakko Kirin Alliance Will Commence a Fragment-based Drug Discovery Project Targeting an Important Protein/Protein Interaction". Strasbourg.

Organisations Organisation Novalix S.A.S.
  Group Novalix (Group)
  Organisation 2 Kyowa Hakko Kirin Co., Ltd.
  Today Kyowa Kirin Co., Ltd.
  Group Kyowa Kirin (Group)
Products Product fragment-based drug discovery services
  Product 2 drug screening (service)
Persons Person Jenn, Stephan (Novalix 201011 President)
  Person 2 Zeyer, Denis (Novalix 201011 CEO)

NovAliX SAS announced today that it has entered into a fragment-based drug discovery project with Kyowa Hakko Kirin Co., Ltd., Japan. This is a continuation of the alliance announced on January 14 of this year and builds upon the positive results already generated by the NovAliX biophysical platform.

The companies will commence research against a new clinically significant target involving the discovery of novel small molecules that modulate protein-protein interaction. First, NovAliX will generate lead candidates using its Graffinity® screening platform. The ensuing "hits" will be elaborated by NovAliX' in-house teams of biophysical and chemistry experts. The biophysical toolbox encompasses a broad spectrum of instrumental techniques employed iteratively to support the activities of synthetic organic, computational and medicinal chemists.

Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.

Stephan Jenn, President of NovAliX, stated, "We in NovAliX are highly excited by this important development in our relationship with Kyowa Hakko Kirin. The collaboration with a leading Japanese pharmaceutical company underlines the value offered by the NovAliX integrated drug discovery platforms; platforms designed and proven to deliver not only hits and but also optimized lead compounds. The extension of the drug discovery alliance to another target validates our capabilities."

About NovAliX

NovAliX is providing enabling chemistry and biophysical technologies to support the pharmaceutical industry's outsourcing needs from discovery to manufacturing. With its proprietary Graffinity SPR technology, X-ray protein crystallography, native mass spectrometry and chemistry NovAliX offers comprehensive integrated services for small molecule drug discovery. With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams. NovAliX Group, a team of 130 scientists, is located in Strasbourg-Illkirch (France) and Heidelberg (NovAliX's Graffinity subsidiary in Germany).

About Kyowa Hakko Kirin

Kyowa Hakko Kirin is a leading biopharmaceutical company in Japan focusing on its core business area of oncology, nephrology and immunology/allergy. Kyowa Hakko Kirin leverages antibody-related leading-edge technologies to discover and develop innovative new drugs aiming to become a global specialty pharmaceutical company which contributes to the health and well-being of people around the world.

Denis Zeyer, CEO
Bld Sébastien Brant, BP 30170
F-67405 Illkirch CEDEX FRANCE
Phone : +33 368 330 200

Record changed: 2019-06-09


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Novalix (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top